Join us live on June 3 for a webinar on how NAMs like 3D in vitro kidney models are reshaping CKD research and drug development. Learn how these immune-competent human-relevant systems can close the gap between lab and clinic. 🔗 Register: https://t.co/gVszDVPhy9 #NAMs

In this customer publication, researchers used MIMETAS’ OrganoReady® Colon Organoid and OrganoTEER® to show how a Lactobacillaceae-derived postbiotic protects the gut barrier, supports recovery, and reduces inflammation. Read it here:

GI toxicity is a major side effect of cancer therapies. Our 3D Colon Organoid Model brings human relevance + high-throughput screening to better predict drug-induced GI toxicity. Explore our poster 👉 https://t.co/qd4YPrnHIW #Toxicology #Organoids #DrugDevelopment #Innovation

📸 Proud moment! Our VP of Biology, Henriette Lanz, presented at #GoodbyeFlatBiology. She shared insight on using patient-derived 3D tumor models to support cell therapy programs by replicating the complex tumor-microenvironment in vitro. #OrgansOnChips #FutureOfBiology

🔬Today on #WorldCancerResearchDay, we recognize the need for research that leads to better cancer treatments and outcomes. At MIMETAS, we support scientists with human 3D models that improve translation from lab to clinic. #CancerResearch #3DCellCulture #Oncology

🚨 #EuroTox Day 2! Meet MIMETAS’ Brian Duggan & Debarati Shome as they present two posters on Risk Prediction and Assessment using NAMs and An Assay-Ready ASC-Derived Colon Organoid Model for Evaluating Therapy-Induced Gastrointestinal Toxicity. #EuroTox2025

📍 We’re at #EuroTox2025! Meet MIMETAS experts Debarati Shome & Brian Duggan to explore how our organ-on-a-chip tech is shaping safety testing & drug development. Don’t miss our posters + connect with us in Athens! #OrganOnAChip #FutureOfToxicology #Innovation

📢 New customer publication! Researchers used our OrganoPlate® platform to develop a Glomerulus-on-a-Chip to show vincristine protects podocytes in FSGS, a major kidney disease. First evidence of its protective effect! Read the publication: https://t.co/tXlkNoTeV5

Meet MIMETAS at #EUROTOX2025 in Athens, Sept 14–17! Connect with our experts Debarati Shome & Brian Duggan to explore our latest 3D human tissue models for toxicity research. Don’t miss our posters on Sept 15 & 16! 🔗 https://t.co/2qEzRRjveE #Toxicology #DrugSafety

Team spirit on the canals! 🚤 Our MIMETAS crew competed in a boating challenge through Leiden, celebrated the winners 🏆, and wrapped it up with a cozy dinner together for our annual company outing. A day of laughter, teamwork & connection!

At MIMETAS, growth is personal. Marketing Specialist Chiwan Chiang shares how curiosity, creativity, and stepping outside your comfort zone shape a career—and a company. 💬 “When you think you have failed, you’ve only gained knowledge.” Full interview: https://t.co/AeayAOzt4c

How do you model lungs more realistically? 🌬️ Find out in our Sept 9 webinar. Register: https://t.co/yUp08WmkRU #OrganonaChip #LungResearch #LungModels

🧠New study from MIMETAS & Roche shows how the ApoE4 Alzheimer’s risk gene alters brain endothelial function & iron transport. Using our iPSC-based BBB model + Roche’s BrainShuttle tech, we found ApoE4-driven changes that shape how drugs reach the brain. https://t.co/R2CZSzWLBg

In this app note, read about a high-throughput 3D human BBB model that has: 🔹 Human-relevant barrier physiology 🔹 Tight junctions & transporter expression 🔹 Predictable response to compounds 🔹 High-throughput with 40–64 perfused chips https://t.co/S21iFH9uhr

In our latest The ‘I’ in MIMETAS feature, Product Design Engineer Frederik Schavemaker shares how intuition, curiosity, and design come together to bring tools like OrganoTEER® to life. 👉 Meet the people behind the biology: https://t.co/YchprZVz9K #TheIinMIMETAS

MIMETAS' Oncology Services help pharma accelerate cancer drug discovery with 3D tumor models that truly mimic human biology. From CAR T cell assays to large-scale screening, we deliver predictive insights for faster, targeted therapies. 🔗 Explore: https://t.co/IbSDIxFMXO

Many immune diseases lack effective treatments. In this webinar, learn how how 3D disease models can improve drug discovery for inflammation & IBD and improve pre-clinical predictability for immune-targeting therapies. Watch now: https://t.co/KzOKUqQS9t #InflammationResearch

Modeling pulmonary fibrosis in vitro remains a challenge due to limited physiological relevance in traditional systems. Our Airway-on-a-Chip (AoC) model offers a more representative approach. 📄 Explore this application in the full poster: https://t.co/NsaGLSy2EQ

The first large-scale phenotypic screen using Organ-on-a-Chip: MIMETAS scientists grew 4,000 perfused micro-vessels and screened 1,537 protein kinase inhibitors. They identified 53 compounds with anti-angiogenic activity - 44 of them previously unknown. https://t.co/DcOGG5QV47

In this whitepaper, explore how human 3D tissue models are transforming immunology drug discovery - boosting accuracy, insights & efficacy. 📊 Real-world case studies on IBD, CKD, vascular inflammation 📥 Read it here: https://t.co/PUVCKm7jCd #Immunology #OrganOnAChip

Together with sanofi, we developed a human immunocompetent kidney-on-a-chip model to study renal inflammation. This tri-culture system enables immune cell migration tracking & drug testing in a 3D flow environment. 📖 Read more: https://t.co/Q8v0gbhfjU #OrganOnChip #CKD